GlassScriptPhysician profile
Joseph M Sack
NPI 1962475343
$21,023.38
in general payments reported to CMS, 2019-2025
20 companies · $3,775 in 2025
The $3,775 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,397 · 2020: $1,036 · 2021: $1,771 · 2022: $1,158 · 2023: $4,773 · 2024: $7,115 · 2025: $3,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $2,233 · Education: $70.00 · Travel and Lodging: $58.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,300.00 |
| Food and Beverage | $2,233.12 |
| Education | $70.00 |
| Travel and Lodging | $58.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15,351.14 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $2,055.60 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,074.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $665.02 | 2019-2025 | Linzess, Creon |
| Abbott Laboratories | $508.09 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $412.58 | 2019-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $175.25 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $154.94 | 2023 | Nuzyra |
| Radius Health, INC. | $114.58 | 2019-2023 | Tymlos |
| Dexcom, INC. | $101.31 | 2024 | Dexcom G7 Gss (161) |
| Pfizer INC. | $90.36 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.61 | 2019 | |
| Sanofi-Aventis U.S. LLC | $68.90 | 2019 | |
| Medicure Pharma INC. | $46.58 | 2020 | |
| Currax Pharmaceuticals LLC | $40.70 | 2023 | Nexletol, Contrave, Nexlizet |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $28.60 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.55 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.71 | 2020 | |
| Merck Sharp & Dohme LLC | $11.68 | 2021 | |
| Qorumpartners | $10.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.